ATE458199T1 - Diagnostische marker der akuten koronaren syndrome und ihre verwendungen - Google Patents

Diagnostische marker der akuten koronaren syndrome und ihre verwendungen

Info

Publication number
ATE458199T1
ATE458199T1 AT06002477T AT06002477T ATE458199T1 AT E458199 T1 ATE458199 T1 AT E458199T1 AT 06002477 T AT06002477 T AT 06002477T AT 06002477 T AT06002477 T AT 06002477T AT E458199 T1 ATE458199 T1 AT E458199T1
Authority
AT
Austria
Prior art keywords
immunoassay
subject
cardiac troponin
threshold level
acute coronary
Prior art date
Application number
AT06002477T
Other languages
English (en)
Inventor
Gunars E Valkirs
Jeffrey R Dahlen
Howard Kirchick
Kenneth F Buechler
Original Assignee
Biosite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26965308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE458199(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biosite Inc filed Critical Biosite Inc
Application granted granted Critical
Publication of ATE458199T1 publication Critical patent/ATE458199T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Error Detection And Correction (AREA)
AT06002477T 2001-05-04 2002-05-04 Diagnostische marker der akuten koronaren syndrome und ihre verwendungen ATE458199T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28887101P 2001-05-04 2001-05-04
US31564201P 2001-08-28 2001-08-28

Publications (1)

Publication Number Publication Date
ATE458199T1 true ATE458199T1 (de) 2010-03-15

Family

ID=26965308

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06002477T ATE458199T1 (de) 2001-05-04 2002-05-04 Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
AT02734211T ATE439588T1 (de) 2001-05-04 2002-05-04 Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02734211T ATE439588T1 (de) 2001-05-04 2002-05-04 Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs

Country Status (8)

Country Link
US (2) US7361473B2 (de)
EP (3) EP1322957B1 (de)
JP (3) JP3806694B2 (de)
AT (2) ATE458199T1 (de)
AU (1) AU2002305394A1 (de)
CA (1) CA2414073A1 (de)
DE (2) DE60233301D1 (de)
WO (1) WO2002089657A2 (de)

Families Citing this family (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991907B1 (en) * 1995-04-18 2006-01-31 Biosite, Inc. Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
US6627404B1 (en) * 1995-04-18 2003-09-30 Biosite, Inc. Methods for improving the recovery of troponin I and T in membranes, filters and vessels
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US20040176914A1 (en) * 2001-04-13 2004-09-09 Biosite Incorporated Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US20040209307A1 (en) * 2001-08-20 2004-10-21 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
DE60233949D1 (de) 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
US6461828B1 (en) 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
NZ539734A (en) * 2002-10-09 2011-07-29 Dmi Biosciences Inc Diagnosis and monitoring of inflammation, ischemia and appendicitis
SG159387A1 (en) * 2002-11-26 2010-03-30 Biocon Ltd In Modified natriuretic compounds, conjugates, and uses thereof
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
JP2006526140A (ja) * 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
CA2522709A1 (en) 2003-04-17 2004-11-04 Ciphergen Biosystems, Inc. Polypeptides related to natriuretic peptides and methods of their identification and use
WO2004097368A2 (en) * 2003-04-28 2004-11-11 Ciphergen Biosystems, Inc. Improved immunoassays
WO2004105575A2 (en) * 2003-05-29 2004-12-09 Trustee Of Darmouth College A method for detecting cardiac ischemia via changes in b-natriuretic peptide levels
JP2007518062A (ja) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
DE10351238A1 (de) * 2003-11-03 2005-06-02 Roche Diagnostics Gmbh Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern
EP1530047A1 (de) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximale Markermoleküle der Arterienthrombose und der Entzündung zur Risikostratifizierung einer koronaren Herzkrankheit
WO2005047882A2 (en) * 2003-11-07 2005-05-26 Princeton Biochemicals, Inc. Multi-dimensional electrophoresis apparatus
GB0329288D0 (en) * 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
US20080175191A1 (en) * 2004-02-23 2008-07-24 Siemens Aktiengesellschaft Method, Intermediate Station and Central Control Unit For the Packet-Switched Data Transmission in a Self-Organizing Radio Network
US20050244892A1 (en) * 2004-02-27 2005-11-03 Lazar Mitchell A Resistin as a marker and therapeutic target for cardiovascular disease
ES2356364T3 (es) * 2004-04-15 2011-04-07 Athera Biotechnologies Ab Anexina v para prevenir la ruptura de la placa.
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
DE102004028303A1 (de) 2004-06-11 2005-12-29 Roche Diagnostics Gmbh Verfahren und Vorrichtung zum Nachweis von Analyten
ES2421556T3 (es) 2004-06-15 2013-09-03 Hoffmann La Roche Utilización de hormonas cardíacas para diagnosticar el riesgo de sufrir complicaciones cardiovasculares como consecuencia de medicamentos cardiotóxicos
EP1615035B1 (de) * 2004-07-07 2007-06-06 F.Hoffmann-La Roche Ag Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
DK1831699T3 (da) * 2004-12-20 2010-03-15 Antibodyshop As Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
CA2595794A1 (en) 2005-01-24 2006-07-27 F. Hoffmann-La Roche Ag The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
EP1691200A1 (de) * 2005-02-14 2006-08-16 F. Hoffmann-La Roche Ag Verwendung des BNP-Art und ANP-Art Peptiden für das Festsetzen der Gefahren von Herzgefäß- Komplikationen als Folge der Volumenüberlastung
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
EP1851541B1 (de) 2005-02-21 2011-05-11 Saga University Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf-erkrankung
WO2006094185A2 (en) * 2005-03-03 2006-09-08 Dmi Biosciences Inc. Quantification of proteins
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20060240444A1 (en) * 2005-04-21 2006-10-26 Peiguo Chu Detection methods
US7300631B2 (en) * 2005-05-02 2007-11-27 Bioscale, Inc. Method and apparatus for detection of analyte using a flexural plate wave device and magnetic particles
CN100422742C (zh) * 2005-05-16 2008-10-01 艾博（武汉）生物技术有限公司 急性心肌梗死早期诊断三合一检测试剂板
EP1904846A4 (de) * 2005-06-29 2009-03-18 Rules Based Medicine Inc Verfahren und kits zur diagnose von akutem koronarsyndrom
ES2288358B1 (es) * 2005-07-01 2008-11-16 Proyecto De Biomedicina Cima, S.L. Marcadores de fibrosis.
JP4850001B2 (ja) * 2005-09-05 2012-01-11 プリマハム株式会社 新規ストレスバイオマーカー及びその用途
CA2624569A1 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for diagnosis of preeclamsia
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US7399598B2 (en) * 2005-10-14 2008-07-15 Taipei Medical University Diagnosis method of endometriosis by detecting biochemical markers and usage of these biochemical markers
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
JP2007131548A (ja) * 2005-11-08 2007-05-31 Hirosaki Univ プロテオグリカンの新規医薬用途
AU2006315274B2 (en) 2005-11-17 2012-07-05 Biogen Ma Inc. Platelet aggregation assays
JP4976412B2 (ja) * 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
US20070172888A1 (en) * 2006-01-25 2007-07-26 Klaus Hallermayer Measuring troponin antibodies to assess cardiovascular risk
EP2005168A4 (de) * 2006-03-09 2009-05-20 Biosite Inc Verfahren und zusammensetzung zur diagnose von krankheiten der aorta
EP1837659B1 (de) * 2006-03-24 2010-06-09 F. Hoffman-la Roche AG Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten
AU2007233320B2 (en) * 2006-04-04 2013-12-12 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
JP6325022B2 (ja) * 2006-04-04 2018-05-16 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
AU2014200749B2 (en) * 2006-04-04 2016-04-14 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP1845379A1 (de) 2006-04-13 2007-10-17 F. Hoffmann-La Roche AG Mittel und Verfahren zur Differenzierung kardialer und pulmonaler Ursachen von Atemnot
PL2386860T4 (pl) 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
US8129135B2 (en) * 2006-04-24 2012-03-06 Medizinische Universität Wien Method for diagnosing cardiovascular diseases
DK2482078T3 (en) * 2006-05-01 2016-05-02 Critical Care Diagnostics Inc Cardiovascular disease diagnosis
SI2019965T1 (sl) * 2006-05-02 2015-10-30 Critical Care Diagnostics, Inc. Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja
US20080118924A1 (en) * 2006-05-26 2008-05-22 Buechler Kenneth F Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
US7935498B2 (en) * 2006-07-07 2011-05-03 Siemens Healthcare Diagnostics Inc. Methods for identifying patients with increased risk of an adverse cardiovascular event
EP1882945A1 (de) 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Differentierung zwischen herz- und lungenbedingten Ursachen für akute Atemnot
KR101245877B1 (ko) 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
WO2008017306A1 (en) * 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
EP1890153A1 (de) 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Herztroponin als Indikator für fortgeschrittene Koronararterienerkrankung
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
US8158374B1 (en) 2006-09-05 2012-04-17 Ridge Diagnostics, Inc. Quantitative diagnostic methods using multiple parameters
DE602006010705D1 (de) 2006-09-15 2010-01-07 Roche Diagnostics Gmbh Biochemische Marker für akute Lungenembolie
EP1901073A1 (de) 2006-09-18 2008-03-19 Roche Diagnostics GmbH Natriuretische Peptide zur Diagnose von Herzkomplikationen infolge von Koronarkatheterisierung
EP1903339B1 (de) * 2006-09-20 2010-08-04 Roche Diagnostics GmbH Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion
PL2084543T3 (pl) 2006-10-26 2018-04-30 B.R.A.H.M.S Gmbh Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
US7842472B2 (en) * 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
EP2095106B1 (de) * 2006-11-14 2013-03-20 Alere San Diego, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenarterienstenose
EP1925943A1 (de) 2006-11-21 2008-05-28 F. Hoffman-la Roche AG Vorrichtungen und Verfahren zur Optimierung von diagnostischen and therapeutischen Ansätzen für chronische Arterienerkrankungen basierend auf dem Nachweis von Troponin T und NT-proBNP.
AU2007325465B2 (en) * 2006-11-28 2013-09-05 Pictor Limited Assay membrane and method of use thereof
DK2115477T3 (en) 2007-01-25 2015-08-10 Hoffmann La Roche USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE
NZ578077A (en) 2007-02-12 2012-04-27 Stefan Hansson Diagnosis of preeclampsia using free foetal haemoglobin
CA2680339C (en) * 2007-03-08 2017-02-28 F. Hoffmann-La Roche Ag Use of slim-1 in the assessment of heart failure
GB0705223D0 (en) * 2007-03-19 2007-04-25 Univ Sussex Method, apparatus and computer program for analysing medical image data
EP2137538B1 (de) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostischer test auf nierenverletzung
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
JP5214723B2 (ja) 2007-04-30 2013-06-19 ナノゲン・インコーポレイテッド 多分析物アッセイ
DE102007022367A1 (de) * 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
JP5570415B2 (ja) * 2007-05-08 2014-08-13 アボット・ラボラトリーズ 他のペプチド型に対する交差反応性の低いヒトｂ型ナトリウム利尿ペプチドアッセイ
EP1998178A1 (de) * 2007-05-29 2008-12-03 F. Hoffman-la Roche AG H-FABP als Prädiktor für Herzinfarkt
EP2167965B1 (de) * 2007-06-22 2013-04-10 B.R.A.H.M.S GmbH Verfahren zur detektion von analyten
ATE533061T1 (de) * 2007-08-03 2011-11-15 Brahms Gmbh Verfahren zur diagnose bakterieller infektionen
EP2031397A1 (de) 2007-08-30 2009-03-04 F. Hoffmann-La Roche AG Surfactantproteine B und D bei der Unterscheidung der Ursachen für Atemnot
JP2011501113A (ja) 2007-10-10 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 急性冠症候群を有する患者での既存の心筋機能不全の評価のためのナトリウム利尿ペプチド／トロポニン比
EP2538218A3 (de) * 2007-11-05 2013-04-24 Nordic Bioscience A/S Biochemische Marker zur Bewertung des CVD-Risikos
EP2215481B2 (de) * 2007-11-15 2017-01-18 Bioporto Diagnostics A/S Diagnostische verwendung individueller molekularer formen eines biomarkers
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
US8013125B2 (en) 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
ES2420841T3 (es) * 2008-03-05 2013-08-27 Mohan Rajapurkar Procedimientos para la detección precoz del síndrome coronario agudo y predicción de acontecimientos cardiacos adversos
CN102016552A (zh) * 2008-03-05 2011-04-13 神谷来克斯公司 用于分子的高灵敏性检测的方法和组合物
US7927880B2 (en) 2008-05-21 2011-04-19 Mohan Rajapurkar Methods and kit for early detection of acute coronary syndrome and prediction of adverse cardiac events
EP2103943A1 (de) 2008-03-20 2009-09-23 F. Hoffman-la Roche AG GDF-15 zur Beurteilung eines kardiovaskulären Risikos hinsichtlich Verabreichung von Entzündungshemmern
PT3093663T (pt) 2008-04-18 2018-10-19 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
WO2009141374A1 (en) 2008-05-21 2009-11-26 F. Hoffmann-La Roche Ag L-fabp, natriuretic peptides and cardiac troponin in individuals in need for a cardiac therapy
EP2294425B1 (de) 2008-05-23 2013-05-22 The Johns Hopkins University Biomarker für myokardischämie
EP2133696A1 (de) 2008-06-10 2009-12-16 Eberhardt Spanuth Sehr geringe Konzentrationen von Troponin I oder T zur Beurteilung eines kardiovaskulären Risikos hinsichtlich der Verabreichung von Entzündungshemmern
JP2011523072A (ja) * 2008-06-13 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病を有する患者の合併症の評価
JP2011528798A (ja) * 2008-07-23 2011-11-24 エフ．ホフマン−ラ ロシュ アーゲー 抗血管形成療法のモニター
EP2148203A1 (de) * 2008-07-23 2010-01-27 BRAHMS Aktiengesellschaft Azurophili-Granulat-Proteasen als Marker bei Herzkrankheiten
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
WO2010017972A1 (en) 2008-08-13 2010-02-18 Roche Diagnostics Gmbh D-dimer, troponin, nt-probnp for pulmonary embolism
WO2010023749A1 (ja) * 2008-08-28 2010-03-04 株式会社 島津製作所 血液試料を用いて心筋虚血状態を評価する方法
JP5540000B2 (ja) * 2008-10-15 2014-07-02 リッジ ダイアグノスティックス，インコーポレイテッド うつ病性障害のヒトバイオマーカーハイパーマッピング
US20120083421A1 (en) * 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
US20100159474A1 (en) * 2008-11-11 2010-06-24 B.R.A.H.M.S. Aktiengesellschaft Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
WO2010059709A2 (en) * 2008-11-18 2010-05-27 Ridge Diagnostics, Inc. Metabolic syndrome and hpa axis biomarkers for major depressive disorder
US8457724B2 (en) * 2008-12-11 2013-06-04 Siemens Medical Solutions Usa, Inc. System for heart performance characterization and abnormality detection
WO2010101255A1 (ja) * 2009-03-05 2010-09-10 味の素株式会社 クローン病診断試薬
PT2406633T (pt) * 2009-03-11 2019-03-14 Augurex Life Sciences Corp Composições e métodos para caracterizar condições artríticas
CA2757659A1 (en) * 2009-04-06 2010-10-14 Ridge Diagnostics, Inc. Biomarkers for monitoring treatment of neuropsychiatric diseases
JP5871791B2 (ja) 2009-04-29 2016-03-01 アカデミス・メディス・セントルム・ベイ・デ・ウニフェルジテイト・ファン・アムステルダムＡｃａｄｅｍｉｓｃｈ Ｍｅｄｉｓｃｈ Ｃｅｎｔｒｕｍ Ｂｉｊ Ｄｅ Ｕｎｉｖｅｒｓｉｔｅｉｔ Ｖａｎ Ａｍｓｔｅｒｄａｍ 心不全または心不全の危険性を中和、予防および／または決定する手段および方法
WO2010138610A2 (en) * 2009-05-26 2010-12-02 The Johns Hopkins University Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
WO2010144358A1 (en) * 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
WO2010143422A1 (ja) * 2009-06-10 2010-12-16 国立大学法人 新潟大学 腎疾患の検査方法
WO2011006072A2 (en) * 2009-07-10 2011-01-13 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
EP2478371B1 (de) 2009-09-17 2016-05-04 Roche Diagnostics GmbH Multimarker-Panel für Linksherzhypertrophie
JP6352588B2 (ja) 2009-10-21 2018-07-04 ザ スクリプス リサーチ インスティテュート 希少ではない細胞を用いて希少細胞を検出する方法
US20120288481A1 (en) 2009-11-09 2012-11-15 The Brigham And Women's Hospital, Inc. Treatment of heart disease
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
EP2568294B1 (de) * 2009-11-13 2015-01-07 BG Medicine, Inc. Risikofaktoren Und Vorhersage Von Myokardinfarkt
US9110086B2 (en) * 2009-11-27 2015-08-18 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
EP3246708A3 (de) 2009-12-18 2018-01-03 Roche Diagnostics GmbH Troponins zur prognose von nierenausfall bei herzchirurgiepatienten
WO2011094308A2 (en) * 2010-01-26 2011-08-04 Ridge Diagnostics, Inc. Multiple biomarker panels to stratify disease severity and monitor treatment of depression
DK2533653T3 (en) 2010-02-12 2015-05-04 Synlab Medizinisches Versorgungszentrum Heidelberg Gmbh Homoarginine AS A biomarker of MORTALITY RISK
PT2550535E (pt) * 2010-03-24 2015-09-07 Preelumina Diagnostics Ab Hbf e a1m como marcadores de fase inicial para pré- eclâmpsia
JP2013525820A (ja) 2010-05-06 2013-06-20 シングレクス、インコーポレイテッド 関節リウマチの発症に関するリスクを診断し、病期分類し、予測し、治療レスポンダーを同定するための方法
EP2388594A1 (de) 2010-05-17 2011-11-23 Roche Diagnostics GmbH Mittel auf GDF-15-Basis sowie Verfahren zur Überlebens- und Genesungsvorhersage bei akuter Entzündung
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
US8602996B2 (en) 2010-06-01 2013-12-10 Cardiac Pacemakers, Inc. Integrating device-based sensors and bedside biomarker assays to detect worsening heart failure
CN101942416B (zh) * 2010-07-23 2012-03-28 中国医学科学院放射医学研究所 抗人心肌肌钙蛋白i特异性单克隆抗体及其制备方法
EP3875599B1 (de) * 2010-07-23 2024-12-11 Astellas Institute for Regenerative Medicine Verfahren zum nachweis seltener subpopulationen von zellen und hochreiner zusammensetzungen aus zellen
WO2012018535A2 (en) * 2010-07-26 2012-02-09 Wellness Indicators, Inc. Wellness panel
WO2012020045A1 (en) 2010-08-10 2012-02-16 Roche Diagnostics Gmbh Method for selecting patients with stable coronary artery disease for pci or medical treatment
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
EP2367006A1 (de) 2010-08-24 2011-09-21 Roche Diagnostics GmbH Mittel und Verfahren auf PLGF-Basis zur Diagnose kardialer Ursachen bei akuten Entzündungen
ES2627337T3 (es) 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
EP2439535A1 (de) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnose von Herzerkrankungen im Zusammenhang mit Diabetes und GDF-15 und Troponin als Prädiktor für die Entwicklung von Diabetes mellitus Typ 2
EP2447720A1 (de) 2010-10-26 2012-05-02 Roche Diagnostics GmbH sFlt1 und Lungenkomplikationen
US8868168B2 (en) 2010-11-11 2014-10-21 Siemens Medical Solutions Usa, Inc. System for cardiac condition characterization using electrophysiological signal data
US8818494B2 (en) 2010-11-29 2014-08-26 Siemens Medical Solutions Usa, Inc. System for ventricular function abnormality detection and characterization
EP2383579A1 (de) 2010-12-17 2011-11-02 F. Hoffmann-La Roche AG sFlt-1, Kardiotroponine und natriuretische Peptide beim Nachweis einer Therapie mit HER-2-Inhibitoren
MX354089B (es) * 2011-01-20 2018-02-09 Cyrex Laboratories Llc Metodos y aparato para la deteccion de sensibilidad al gluten y su diferenciacion de la enfermedad celiaca.
GB2490652A (en) * 2011-04-18 2012-11-14 Microtest Matrices Ltd Methods of quantifying antibodies, especially IgE antibodies in a sample
US8754044B2 (en) 2011-05-03 2014-06-17 Northwestern University Neuroprotection by hepatic cells and hepatocyte secretory factors
US8684942B2 (en) 2011-05-25 2014-04-01 Siemens Medical Solutions Usa, Inc. System for cardiac impairment detection based on signal regularity
EP2385373A1 (de) 2011-07-01 2011-11-09 F. Hoffmann-La Roche AG Natriuretische Peptide bei der Schwangerschaft
US20120258477A1 (en) * 2011-07-25 2012-10-11 Northwestern University Fecal neopterin concentration measurement as an indicator of disease activity in inflammatory bowel disease
EP2581040A1 (de) 2011-10-10 2013-04-17 Roche Diagnostics GmbH TNT-basiertes Herzhypertrophierisiko im Zusammenhang mit physiologischem Training und Führung in Athleten
EP3088900B1 (de) 2011-10-17 2020-08-12 Roche Diagniostics GmbH Troponin als marker für intermittierendes vorhofflimmern
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
PL3553084T3 (pl) 2011-11-16 2023-04-17 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan
HRP20190122T1 (hr) 2011-11-16 2019-03-08 Adrenomed Ag Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
HRP20191771T1 (hr) 2011-11-16 2019-12-27 Adrenomed Ag Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije
US9140696B2 (en) 2011-11-16 2015-09-22 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
WO2013079567A2 (en) 2011-12-01 2013-06-06 Roche Diagnostics Gmbh Nt-proanp and nt-probnp for the diagnosis of stroke
CN103163295B (zh) * 2011-12-08 2015-11-18 吴宗贵 一种用于急性冠脉综合征的液相芯片试剂盒以其制备方法
AU2012351504C1 (en) * 2011-12-15 2018-04-26 Mycartis N.V. Biomarkers and parameters for preeclampsia
JP5814800B2 (ja) * 2011-12-28 2015-11-17 株式会社Ｌｓｉメディエンス 神経変性疾患の検出方法
EP2620773B1 (de) 2012-01-26 2015-03-18 Roche Diagniostics GmbH Verfahren zur Differenzierung eines Vor- und Rückwärtsherzversagens
CN104136072B (zh) * 2012-01-31 2016-08-24 心脏起搏器公司 使用生物标记物组数据诊断心力衰竭的可植入装置和方法
CN104159638A (zh) 2012-01-31 2014-11-19 心脏起搏器公司 用于使用生物标记物组数据控制心脏再同步装置/疗法的系统和方法
EP2650684A1 (de) 2012-04-10 2013-10-16 Roche Diagniostics GmbH Diagnose auf Pro-SP-B und NT-proBNP bei Patienten mit Lungenentzündung
US8903480B2 (en) 2012-04-11 2014-12-02 Siemens Medical Solutions Usa, Inc. System for cardiac condition detection using heart waveform area associated analysis
WO2013163269A1 (en) * 2012-04-24 2013-10-31 Sri International Human serum biomarkers of prostate cancer and sars-cov
EP2615459A1 (de) 2012-04-27 2013-07-17 Roche Diagniostics GmbH Verfahren zur Diagnose von Distalbronchoalveolargewebeschäden in Asthma durch Erkennen von proSP-B
US20150141278A1 (en) * 2012-05-30 2015-05-21 Clarient Diagnostic Services, Inc. Multiplexed assay method for lung cancer classification
JPWO2013183725A1 (ja) * 2012-06-06 2016-02-01 国立大学法人九州大学 非ヒトモデル動物、非ヒトモデル動物の作製方法及び抗血栓薬のスクリーニング方法
EP2600155A1 (de) 2012-06-18 2013-06-05 Roche Diagniostics GmbH sFlt-1-basierte Diagnose und Überwachung von Schlaganfallpatienten
EP2597466A1 (de) 2012-06-26 2013-05-29 Roche Diagniostics GmbH Mittel und Verfahren zur proSP-B-basierten Diagnose von Alveolenbeschädigung bei Patienten mit pulmonaler Hypertonie
EP2597467A1 (de) 2012-06-26 2013-05-29 Roche Diagniostics GmbH Mittel und Verfahren zur proSP-B-basierten Diagnose von Lungenstauung bei Patienten mit akutem Koronarsyndrom
WO2014009418A1 (en) 2012-07-10 2014-01-16 Roche Diagnostics Gmbh TnT, NTproBNP, sFlt-1 for CURB65 IN PNEUMONIA
IN2015DN01767A (de) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
EP3428649B1 (de) 2012-09-12 2022-03-23 Roche Diagnostics GmbH Identifizierung von patienten mit abnormaler fraktionsverkürzung
JP6392762B2 (ja) * 2012-10-02 2018-09-19 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 女性対象において癌になるリスクの予測を補助するための方法
US20140273273A1 (en) 2012-11-01 2014-09-18 Christie Mitchell Ballantyne Biomarkers to improve prediction of heart failure risk
ES2774288T3 (es) 2012-11-09 2020-07-20 Hoffmann La Roche Diagnóstico basado en TnT o BNP de fibrilación auricular paroxística
EP2730923A1 (de) 2012-11-09 2014-05-14 Roche Diagniostics GmbH NTproBNP- und cTnT-basierte Therapieanleitung bei Herzversagen
EP2925337B1 (de) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutante ngal-proteine und verwendungen davon
CA2893639C (en) 2012-12-04 2021-01-05 F. Hoffmann-La Roche Ag Biomarkers in the selection of therapy of heart failure
DE102012223378A1 (de) * 2012-12-17 2014-06-18 Charité - Universitätsmedizin Berlin In-vitro Verfahren und Kit zur Diagnose von akutem Koronarsyndrom
KR20150099775A (ko) * 2012-12-20 2015-09-01 국립대학법인 홋가이도 다이가쿠 전립선 기저세포의 검출 방법
US20160116472A1 (en) * 2013-02-04 2016-04-28 The General Hospital Corporation Biomarkers for stroke diagnosis
KR101494882B1 (ko) * 2013-02-21 2015-02-25 한국과학기술연구원 급성 심근 경색 진단용 조성물, 그 조성물을 포함하는 급성 심근 경색 진단용 키트 및 급성 심근 경색 진단 방법
US9020583B2 (en) 2013-03-13 2015-04-28 Siemens Medical Solutions Usa, Inc. Patient signal analysis and characterization
EP2866033A1 (de) 2013-10-23 2015-04-29 Roche Diagniostics GmbH Differenzialdiagnose von akuter Atemnot auf Basis von c-terminiertem proSP-B, KL-6 und BNP-Peptiden
US20160231334A1 (en) * 2013-10-28 2016-08-11 The Forsyth Institute Compositions and Methods for Evaluating Metabolic Syndrome and Related Diseases
EP3066476A2 (de) 2013-11-04 2016-09-14 The Regents of the University of Michigan Biomarker und verfahren zur progressionsvorhersage für chronische nierenerkrankung
AU2014351090A1 (en) * 2013-11-15 2016-06-16 Otago Innovation Limited Biomarker for cardiac disorders
EP3099821B1 (de) * 2014-01-27 2021-08-11 Epic Sciences, Inc. Diagnostika für zirkulierende tumorzellen zum nachweis von neuroendokrinem prostatakrebs (nepc)
ES2712201T3 (es) 2014-01-28 2019-05-09 Hoffmann La Roche Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B
US10545151B2 (en) 2014-02-21 2020-01-28 Epic Sciences, Inc. Methods for analyzing rare circulating cells
EP2916134B1 (de) 2014-03-05 2017-08-16 Roche Diagnostics GmbH Verwendung von Seprase zur Differenzialdiagnose von akuter Atemnot
ES2939018T3 (es) 2014-03-26 2023-04-18 Hoffmann La Roche IGFBP7 para diagnosticar una disfunción diastólica
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
HUE047951T2 (hu) 2015-01-09 2020-05-28 Global Genomics Group Llc Vér alapú biomarkerek atheroszklerotikus koszorúsér betegség diagnosztizálására
EP3411721A1 (de) 2016-02-04 2018-12-12 Metanomics GmbH Mittel und verfahren zur differenzierung zwischen herzinsuffizienz und lungenerkrankung bei einer person
EP3440467B1 (de) * 2016-04-08 2020-05-13 Lunginnov Verfahren zur diagnose von postoperativen lungenentzündungen bei patienten nach einer operation
ES2817087T3 (es) 2016-08-04 2021-04-06 Hoffmann La Roche ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular
WO2018069487A1 (en) 2016-10-14 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of loss of renal function in patients with type 2 diabetes
WO2018127372A1 (en) 2016-12-13 2018-07-12 Witteman Johanna Cornelia Maria Detection of transient troponin peaks for diagnosis of subjects at high risk of cardiovascular disease
EP3360570A1 (de) 2017-02-13 2018-08-15 Roche Diagnostics GmbH Monoklonale antikörper für nt-probnp punktmutationen
US20210018507A1 (en) * 2018-03-04 2021-01-21 Mazumdar Shaw Medical Foundation Sall.ivary protein biomarkers for the diagnosis and prognosis of head and neck cancers, and precancers
WO2019189744A1 (ja) * 2018-03-30 2019-10-03 栄研化学株式会社 新規大動脈瘤マーカー
EP3572813A1 (de) * 2018-05-22 2019-11-27 Centre National de la Recherche Scientifique Diagnoseverfahren von multipler sklerose
IT201800007264A1 (it) * 2018-07-17 2020-01-17 Metodo per la diagnosi in vitro di carcinoma della prostata mediante biomarcatori urinari
BR112021001798A2 (pt) 2018-07-31 2021-04-27 F. Hoffmann-La Roche Ag métodos para avaliar a fibrilação atrial, para diagnosticar insuficiência cardíaca, para auxiliar na avaliação da fibrilação atrial, para prever o risco de acidente vascular cerebral e para aprimorar a precisão da previsão, usos e kit
WO2020030803A1 (en) 2018-08-10 2020-02-13 F. Hoffmann-La Roche Ag Ces-2 (carboxylesterase-2) for the assessment of afib related stroke
JP7518061B2 (ja) 2018-08-16 2024-07-17 エフ． ホフマン－ラ ロシュ アーゲー 心房細動および抗凝固療法の評価における循環ｔｆｐｉ－２（組織因子経路阻害剤２）
CN113260863A (zh) 2018-08-17 2021-08-13 豪夫迈·罗氏有限公司 用于心房纤颤的评价中的循环bmp10 (骨形态发生蛋白10)
WO2020039001A1 (en) 2018-08-22 2020-02-27 Roche Diagnostics Gmbh Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation
KR20210049829A (ko) 2018-08-24 2021-05-06 에프. 호프만-라 로슈 아게 심방 세동의 사정에서 및 뇌졸중의 예측을 위한 순환하는 fgfbp-1 (섬유모세포 성장 인자-결합 단백질 1)
WO2020064995A1 (en) 2018-09-28 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of biomarkers representing cardiac, vascular and inflammatory pathways for the prediction of acute kidney injury in patients with type 2 diabetes
CN111192687A (zh) * 2018-11-14 2020-05-22 复旦大学附属儿科医院 一种进展期阑尾炎列线图预测模型及其用途
US20220196678A1 (en) * 2019-02-21 2022-06-23 B.R.A.H.M.S. Gmbh Method for the diagnosis of macce in patients who underwent gastrointestinal surgery
US20220196674A1 (en) * 2019-04-17 2022-06-23 Abdolamir Landi Treatment of autoimmune liver disease
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
JP7490677B2 (ja) 2019-05-23 2024-05-27 エフ． ホフマン－ラ ロシュ アーゲー ＨＦｐＥＦのためのＩＧＦＢＰ７の比
WO2021026362A1 (en) * 2019-08-07 2021-02-11 Edifice Health, Inc. Treatment of prevention of cardiovascular disease
CN115190886B (zh) 2020-02-20 2026-04-28 马斯特里赫特大学 循环bmp10（骨形态发生蛋白10）的检测方法
WO2022025773A1 (en) 2020-07-29 2022-02-03 Pictor Limited Immunoassay for sars-cov-2 antibodies
EP4222499A1 (de) 2020-09-30 2023-08-09 F. Hoffmann-La Roche AG Zirkulierendes total-nt-probnp (glycosyliertes und unglycosyliertes nt-probnp) und sein verhältnis mit nt-probnp (unglycosyliertem nt-probnp) bei der beurteilung von vorhofflimmern
CN114182010B (zh) * 2022-01-11 2022-06-07 首都医科大学附属北京朝阳医院 一种血浆外泌体circRNA标志物及其应用
CN118871785A (zh) 2022-03-18 2024-10-29 豪夫迈·罗氏有限公司 用于2型与1型急性心肌梗死的早期辨别的肌钙蛋白标志物组合
US20250232875A1 (en) 2022-03-18 2025-07-17 Roche Diagnostics Operations, Inc. Cmybpc marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction
CN115356486A (zh) * 2022-08-19 2022-11-18 华中科技大学同济医学院附属同济医院 一种变异型心绞痛的辅助诊断试剂、试剂盒及其应用
WO2024100050A1 (en) 2022-11-07 2024-05-16 Hôpitaux Universitaires Saint-Louis-Lariboisière Rapid optimization of oral heart failure therapies helped by nt-probnp testing
EP4365598A1 (de) 2022-11-07 2024-05-08 Hôpitaux Universitaires Saint-Louis-Lariboisière Schnelle optimierung von oralen herzinsuffizienztherapien mithilfe von nt-probnp-tests
CN115902237B (zh) * 2022-11-09 2024-09-27 哈尔滨医科大学 用于判断急性心肌梗死后心源性猝死的生物标志物及其应用
CN120677386A (zh) 2023-01-30 2025-09-19 豪夫迈·罗氏有限公司 患有心血管疾病的受试者中由钠-葡萄糖协同转运蛋白抑制剂(SGLTi)诱导的效应
WO2024190857A1 (ja) * 2023-03-15 2024-09-19 住友ベークライト株式会社 動脈硬化性疾患を診断するための試薬および方法
EP4767065A1 (de) 2023-08-22 2026-07-01 Roche Diagnostics GmbH Überwachung von kardiovaskulären markern in interstitieller flüssigkeit und ihre anwendung bei der beurteilung von herzversagen
KR20260038939A (ko) 2023-08-23 2026-03-19 에프. 호프만-라 로슈 아게 전기화학적 면역분석법
EP4685484A1 (de) 2024-07-25 2026-01-28 Target Cells Spólka z ograniczona odpowiedzialnoscia Verfahren, assay und verwendung von saueren alpha-1 glykoprotein zur bestimmung der bindungskapazität von stammzellen

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5206140A (en) * 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US5422393A (en) * 1988-07-11 1995-06-06 Naturon Pharmaceutical Corporation Natriuretic hormone
US5939272A (en) * 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) * 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
EP0479948B1 (de) * 1989-06-23 1998-08-26 Genentech, Inc. Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
US5922615A (en) * 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) * 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
CA2027434C (en) * 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5955377A (en) * 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) * 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (de) * 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden
US6143576A (en) * 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) * 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US5494829A (en) * 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US6147688A (en) * 1993-06-28 2000-11-14 Athena Design Systems, Inc. Method and apparatus for defining and selectively repeating unit image cells
US5824799A (en) * 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US5795725A (en) * 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
PT914344E (pt) * 1996-03-04 2005-10-31 Scios Inc Ensaio e reagentes para a quantificacao de hbnp
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
US6113855A (en) * 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US6156521A (en) * 1997-12-19 2000-12-05 Biosite Diagnostics, Inc. Methods for the recovery and measurement of troponin complexes
US5947124A (en) * 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) * 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
KR100546223B1 (ko) 1997-04-30 2006-01-26 마루하 주식회사 허혈성질환의 검출 또는 예지방법과 그 검출용키트
US6117644A (en) * 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
US6171870B1 (en) * 1998-08-06 2001-01-09 Spectral Diagnostics, Inc. Analytical test device and method for use in medical diagnoses
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
EP1117680A2 (de) 1998-09-29 2001-07-25 Lars Christian B. Ronn Ncam-bindende verbindungen
CA2263063C (en) 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
AT407580B (de) 1999-08-20 2001-04-25 Biomedica Gmbh Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay
AUPQ893300A0 (en) 2000-07-21 2000-08-17 Newbrain Technologies Pty Limited Method and system for utilising database information
US6670138B2 (en) * 2000-11-01 2003-12-30 Agy Therapeutics, Inc. Method of diagnosing ischemic stroke via UCP-2 detection
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
ATE380175T1 (de) * 2001-06-27 2007-12-15 Smithkline Beecham Corp Pyrrolidine als dipeptidyl peptidase inhibitoren
US6627457B2 (en) * 2001-07-30 2003-09-30 Quest Diagnostics Investments Incorporated Methods for detecting pregnancy
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.

Also Published As

Publication number Publication date
DE60233301D1 (de) 2009-09-24
EP1322957A2 (de) 2003-07-02
ATE439588T1 (de) 2009-08-15
US20030109420A1 (en) 2003-06-12
EP1666881A2 (de) 2006-06-07
EP1322957B1 (de) 2009-08-12
WO2002089657A2 (en) 2002-11-14
DE60235416D1 (de) 2010-04-01
EP1666881B1 (de) 2010-02-17
US7358055B2 (en) 2008-04-15
EP2261669A1 (de) 2010-12-15
EP1666881A3 (de) 2007-09-19
US7361473B2 (en) 2008-04-22
WO2002089657A3 (en) 2003-02-27
US20060063204A1 (en) 2006-03-23
JP4235652B2 (ja) 2009-03-11
JP2004520598A (ja) 2004-07-08
AU2002305394A1 (en) 2002-11-18
CA2414073A1 (en) 2002-11-14
JP2006234823A (ja) 2006-09-07
JP2005121664A (ja) 2005-05-12
JP3806694B2 (ja) 2006-08-09
EP1322957A4 (de) 2005-11-02

Similar Documents

Publication Publication Date Title
DE60235416D1 (de) Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen
DE602004001533D1 (de) Immunotestverfahren für Herz-Troponin I
Leff et al. Further concerns over Cheng-Prusoff analysis
WO2001057522A3 (en) Immunochromatographic methods which employ semiconductor nanocrystals
DK0539477T3 (da) Fremgangsmåde til forstærkning af emissionssignalet af en luminescerende forbindelse
DE60227763D1 (de) Verwendung eines natriuretischen peptids vom b-typ als prognostischer indikator bei akuten koronaren syndromen
BRPI9816332B8 (pt) tira de teste de biossensor eletroquímico aperfeiçoada
ATE281648T1 (de) Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays
ATE496298T1 (de) Methode um die sensitivität einer luminesenz assay zu erhöhen
US20100285493A1 (en) Method for determining amino-terminal proanp in patients having a cardiac disease or being suspected of developing or having a cardiac disease
ATE333522T1 (de) Verfahren zur bestimmung von mehrere analyten
DE69132864D1 (de) Antikörper gegen hypophysäre adenylatzyklase aktivierende peptid-pacap, hybridome und bestimmung von pacap
ATE240522T1 (de) Chemilumineszenz-immunoassay zum nachweis eines mit der chagas-erkränkung verbundenen analyts in einer probe
AU3534001A (en) Method for identifying a mark applied on a solid body
DE59009452D1 (de) Verwendung von zweiwertigen Kationen in immunchemischen Tests.
ATE284955T1 (de) Map-kinase: polypeptide, polynukleotide und ihre verwendung
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
DE60332479D1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
RU2001123102A (ru) Способ эксплуатации двигателя
DK1210606T3 (da) Bruskresorptionsassays
RU2001133157A (ru) Способ оценки микротвердости
DE50011831D1 (de) Dynamische bestimmung von analyten durch arrays auf inneren oberflächen
SE0100595D0 (sv) Immunological detection of prostate diseases and prostatic-related diseases
ES2063732T1 (es) Equipo y ensayo para determinar un antigeno/anticuerpo en una muestra.
ATE260936T1 (de) 5-hydroxytryptophol (5-htol) derivate, antikörper,immunoassays und detektion von kürzfristigem alkoholkonsum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties